Although people have greater access to personalized drugs and tests than ever before, a survey by GenomeWeb and the PMC shows public awareness isn't improving.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
Geisinger is hoping to help others around the country implement precision medicine, which requires significant investment in genomics expertise, as well as infrastructural and operational changes.
The law contains provisions that proponents say will advance precision medicine and speed new tests to market, but critics worry if this will come at a cost to public health.
NIH has been conservative on the PMI's budget and its funds are sufficient to launch enrollment next year, begin collecting data, and initiate genetic testing pilot projects.
Personalized medicine proponents are uncertain where funding, personnel, and priorities will land in a new administration and Congress.
A beta-testing community is providing feedback on the PMI's recruitment efforts, which are slated to kick off in the first quarter of 2017.